{"classes":[{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG000","spread":"NA","value":"1.04"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG001","spread":"NA","value":"0.64"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG002","spread":"NA","value":"0.64"},{"groupId":"OG003","spread":"36.67","value":"0.74"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG004","spread":"NA","value":"0.75"},{"groupId":"OG005","spread":"17.66","value":"0.68"},{"groupId":"OG006","spread":"13.47","value":"1.06"},{"groupId":"OG007","spread":"29.24","value":"0.67"},{"groupId":"OG008","spread":"47.64","value":"0.33"},{"groupId":"OG009","spread":"45.70","value":"0.81"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG010","spread":"NA","value":"0.87"},{"groupId":"OG011","spread":"33.69","value":"1.01"},{"groupId":"OG012","spread":"20.27","value":"0.75"},{"groupId":"OG013","spread":"82.45","value":"0.81"},{"groupId":"OG014","spread":"24.96","value":"0.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"7"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"11"},{"groupId":"OG014","value":"2"}],"units":"Participants"}],"description":"Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. Accumulation ratio was calculated by taking ratio of AUC(0-24) in Week 2 Day 7 to AUC (0-24) in Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 5 mg QD"},{"description":"Participants were administered once daily oral dose of 10 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 10 mg QD"},{"description":"Participants were administered once daily oral dose of 20 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 20 mg QD"},{"description":"Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 30 mg QD MM"},{"description":"Participants were administered once daily oral dose of 40 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 40 mg QD"},{"description":"Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 40 mg QD MM"},{"description":"Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 60 mg QD AML"},{"description":"Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 60 mg QD NHL"},{"description":"Participants with MM were administered once daily oral dose of 60 mg GSK525762.","id":"OG008","title":"Part 1: GSK525762 60 mg QD MM"},{"description":"Participants with AML were administered once daily oral dose of 75 mg GSK525762.","id":"OG009","title":"Part 1: GSK525762 75 mg QD AML"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG010","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants with AML were administered once daily oral dose of 80 mg GSK525762.","id":"OG011","title":"Part 1: GSK525762 80 mg QD AML"},{"description":"Participants with NHL were administered once daily oral dose of 80 mg GSK525762.","id":"OG012","title":"Part 1: GSK525762 80 mg QD NHL"},{"description":"Participants with AML were administered once daily oral dose of 100 mg GSK525762.","id":"OG013","title":"Part 1: GSK525762 100 mg QD AML"},{"description":"Participants with AML were administered once daily oral dose of 120 mg GSK525762.","id":"OG014","title":"Part 1: GSK525762 120 mg QD AML"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose","title":"Part 1: Accumulation Ratio (RO) of GSK525762","type":"SECONDARY","unitOfMeasure":"Ratio"}